Table 2.
Treatment-related patient characteristics
| Total (%) n = 275 | Age <70 years (%) n = 228 | Age ≥ 70 years (%) n = 47 | p value for group differences | |
|---|---|---|---|---|
|
Type of surgery |
|
|
|
0.019b |
| Primary cytoreduction |
226 (82.2) |
193 (84.6) |
30 (70.2) |
|
| Interval debulking |
49 (17.8) |
35 (15.4) |
14 (29.8) |
|
|
Surgical interventions |
|
|
|
|
| Adnectomy |
259 (94.2) |
220 (96.4) |
39 (83.0) |
0.038b |
| Hysterectomy |
248 (90.2) |
212 (93.0) |
36 (76.6) |
0.006b |
| Omentectomy |
255 (92.7) |
212 (93.0) |
43 (91.5) |
0.720b |
| Pelvic LAE |
191 (69.5) |
171 (75.0) |
20 (42.6) |
<0.001b |
| Paraaortic LAE |
184 (66.9) |
166 (72.8) |
18 (38.3) |
<0.001b |
| Appendectomy |
110 (40.0) |
94 (41.2) |
16 (34.0) |
0.327b |
| Splenectomy |
22 (8.0) |
19 (8.3) |
3 (6.4) |
1.000b |
| Large bowel resection |
104 (37.8) |
87 (38.2) |
17 (36.2) |
0.798b |
| Small bowel resection |
37 (13.4) |
27 (11.8) |
10 (21.3) |
0.084b |
|
Postop. residual tumor |
|
|
|
0.029b |
| Microscopic |
189 (68.7) |
163 (71.5) |
26 (55.3) |
|
| Macroscopic |
86 (31.3) |
65 (28.5) |
21 (44.7) |
|
|
Intraoperative complications |
|
|
|
0.532c |
| Yes |
20 (7.2) |
16 (7.0) |
4 (8.5) |
|
| No |
247 (89.9) |
209 (91.7) |
38 (80.9) |
|
| Unknown |
8 (2.91) |
3 (1.3) |
5 (10.6) |
|
|
Postoperative complications |
|
|
|
0.495b |
| Yes |
95 (34.6) |
82 (36.0) |
13 (27.7) |
|
| No |
172 (62.6) |
143 (62.7) |
29 (61.7) |
|
| Unknown |
8 (2.9) |
3 (1.3) |
5 (10.6) |
|
|
Mortality rates |
|
|
|
|
| 30d-mortality rate |
0.0 % |
0.0 % |
0.0 % |
1.000d |
| 60d-mortality rate |
1.1 % |
0.4 % |
2.1 % |
<0.001d |
|
Chemotherapy |
|
|
|
|
| courses (median, range) |
6 (1–8) |
6 (1–8) |
6 (2–6) |
0.156a |
| Time to chemo after surgery (median, range) |
34 (5–188) |
34 (5–188) |
31.5 (9–127) |
0.368a |
| Treatment concept |
|
|
|
0.019b |
| - Neoadjuvant |
49 (17.8) |
35 (15.4) |
14 (29.8) |
|
| - Adjuvant |
226 (82.2) |
193 (84.6) |
30 (70.2) |
|
| Treatment regimen |
|
|
|
<0.001c |
| - Platinum-based combination |
260 (94.5) |
223 (97.8) |
37 (78.7) |
|
| - Platinum monotherapy |
15 (5.5) |
5 (2.2) |
10 (21.3) |
|
|
Response to chemotherapy |
205 (74.5) |
178 (78.4) |
27 (57.4) |
0.003b |
|
Optimal oncologic treatment (no residual tumor + combination therapy) |
|
|
|
<0.001b |
| Yes |
179 (65.1) |
160 (70.1) |
19 (40.4) |
|
| No |
96 (34.1) |
68 (29.8) |
28 (59.6) |
|
|
Survival(months) |
|
|
|
|
| Median PFS |
19 |
20 |
12 |
0.022d |
| Median OS | 48 | 64 | 30 | <0.001d |
Detailed overview of surgical procedures, chemotherapy and prognostic aspects. Parameters were separately analyzed for elderly patients ≥70 years and patients younger than 70 years.
a Man-Whitney-U-test, b Chi2-test, c Fisher’s exact test, d log-rank test.
LAE = lymphadenectomy, PFS = progression free survival, OS = overall survival.